Unjha Formulations Peer Comparison

BSE: 531762

₹26.00

₹0.75 (2.97%)

As on 26-Aug-2026IST

Market cap

₹12 Cr

Revenue (TTM)

₹15 Cr

P/E Ratio

24.8

P/B Ratio

2.9

Div. Yield

0 %

Edit

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Market cap (₹ Cr)	12	35,331	30,553	30,224	30,043
Revenue (₹ Cr)	15	9,683	3,564	2,372	1,936
Net Profit (₹ Cr)	0.47	1,018.97	414.00	497.77	288.22
Net Margin (%)	3.05	10.47	11.23	20.72	14.79
RoE (%)	11.48	21.30	8.38	28.49	29.77
Price to Earnings	24.79	34.93	74.70	60.72	104.24
Price-To-Book	2.91	6.74	6.07	14.95	22.38

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Operating Revenue	15.59	7,896.00	3,373.00	2,022.99	1,753.96
Total Income	15.75	7,968.78	3,510.00	2,053.15	1,762.66
Total Expenditure	14.65	6,427.14	2,747.00	1,448.49	1,354.69
EBITDA	0.94	1,468.85	626.00	574.50	399.26
Depreciation	0.14	384.13	227.00	91.74	45.26
EBIT	0.80	1,084.73	399.00	482.76	354.00
Interest	0.01	175.78	213.00	23.95	42.17
Other Income	0.16	72.79	137.00	30.17	8.70
Exceptional Items	--	-10.38	-85.00	76.40	--
Profit before Tax	0.95	971.35	238.00	488.98	320.53
Provision for Tax	0.25	263.88	39.00	124.98	73.80
Profit after Tax	0.70	707.47	199.00	364.00	246.74

Liabilities (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Shareholder's Funds	3.84	4,446.19	4,940.00	1,874.47	1,288.82
Minority Interest	--	195.37	341.00	--	0.00
Non-Current Liabilities	0.00	811.91	1,235.00	345.47	189.02
Current Liabilities	1.67	2,668.27	1,622.00	710.20	835.87
Total Liabilities	5.51	8,121.73	8,578.00	2,930.14	2,326.71

Assets (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Non-Current Assets	1.30	3,565.87	5,441.00	1,447.01	631.90
Current Assets	4.21	4,555.86	2,606.00	1,483.13	1,681.81
Total Assets	5.51	8,121.73	8,578.00	2,930.14	2,326.71
Total Debt*	0.00	730.70	2,125.00	196.61	259.37
Net Current Assets	2.55	1,887.59	984.00	772.93	845.94
Contingent Liabilities	8.80	393.94	768.26	13.18	19.09

Cashflow (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Cash From Operating Activities	1.24	851.71	390.00	346.68	205.05
Cash Flow from Investing Activities	-0.23	-94.00	-241.00	-423.73	-409.72
Cash from Financing Activities	-0.01	-813.96	-54.00	20.98	283.07
Net Cash Inflow / Outflow	1.00	-56.25	95.00	-56.08	78.39

Ratios

Profitability Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
ROCE (%)	27.54	22.49	6.79	27.50	29.22
ROE (%)	20.19	19.19	4.29	21.43	27.84
ROA (%)	14.00	8.94	2.53	14.25	13.11
EBIT Margin (%)	7.08	19.52	22.62	29.89	23.26
Net Margin (%)	4.47	8.88	5.67	17.73	14.00
Cash Profit Margin (%)	5.43	13.61	10.98	22.53	7.71

Growth Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Revenue Growth (%)	12.43	18.59	11.99	36.98	36.57
EBIT Growth (%)	75.16	19.81	67.69	75.89	52.29
Net Profit Growth (%)	72.93	34.10	449.12	39.94	83.64
EPS Growth (%)	72.93	30.75	553.20	39.94	71.44
Book Value Growth (%)	22.45	50.94	13.47	22.95	144.31

Valuation Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Price / Earnings	12.90	29.84	89.54	42.34	51.69
Price / Book Value	2.37	4.58	3.87	8.23	10.14
Dividend Yield (%)	0.00	0.28	0.00	0.28	0.19
EV/EBITDA	6.75	13.55	27.45	25.23	31.05
Market Cap (₹ Cr)	9.09	20,327.45	19,071.62	15,412.11	12,753.19

Solvency Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Debt to Equity	0.00	0.16	0.43	0.10	0.21
Short term debt to equity ratio	--	0.11	0.09	--	0.05
Current Ratio	2.53	1.71	1.61	2.09	2.01
Quick Ratio	2.15	0.98	1.06	1.37	1.14
Interest Coverage	123.28	6.53	2.12	21.42	8.60

Operating Efficiency Ratios

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Neuland Lab	Rubicon Research
Debtors to sales (%)	8.65	25.36	17.43	26.76	29.00
Asset Turnover	3.10	1.01	0.49	0.79	2.01
Receivable days	33.45	87.83	58.75	77.32	40.13
Inventory Days	19.48	78.64	75.82	80.83	60.29
Payable days	37.68	174.97	186.21	125.94	232.47
Cash Conversion Cycle	15.25	-8.50	-51.64	32.22	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly